Clinical Trials at University of Arkansas for Medical Sciences
As of August 2026, 101 paid clinical trials are recruiting at University of Arkansas for Medical Sciences, located at 4301 W MARKHAM ST, LITTLE ROCK, AR 72205-7101, phone (501) 614-2830 in Little Rock, Arkansas. Active studies at this site cover conditions such as Schizophrenia, Acute Myeloid Leukemia and Duchenne Muscular Dystrophy. Compensation typically covers time, travel, and study visits — most studies also offer study-related medical care at no cost to participants.
Recruiting trial data synced daily from ClinicalTrials.gov. Last sync: .
Filter results
Newly added in Little Rock
Posted to ClinicalTrials.gov within the last 60 days — these studies are just starting to recruit.
102 clinical trials at University of Arkansas for Medical Sciences
·Clear filters·A Study of Vepugratinib (LY3866288) in Participants With Cancer in the Urinary Tract
A Study With Combinations of Anti-LAG-3 and Anti-PD-1 Antibodies in Adult Participants With Advanced or Metastatic Melanoma (Harmony Head-to-Head)
A Study to Evaluate the Efficacy and Safety of Tulisokibart (MK-7240) in Participants With Moderate to Severe Crohn's Disease (MK-7240-008)
A Study to Assess Adverse Events and How Intravenously (IV) Infused Telisotuzumab Vedotin (ABBV-399) Moves Through the Body as a Monotherapy in Adult Participants With Previously Treated Non-Squamous Non-Small Cell Lung Cancer (NSCLC)
MILD® Percutaneous Image-Guided Lumbar Decompression: A Medicare Claims Study
A Study to Evaluate XEN1101 as Adjunctive Therapy in Primary Generalized Tonic-Clonic Seizures
A Phase 2 Study of ACR-368 in Endometrial Adenocarcinoma
A Study to Investigate the Efficacy and Safety of Bemdaneprocel in Adults Who Have Parkinson's Disease
Pompe Disease Registry Protocol
Fabry Disease Registry & Pregnancy Sub-registry
Study of NRTX-1001 Neural Cell Therapy in Drug-Resistant Unilateral Mesial Temporal Lobe Epilepsy (EPIC (EPIlepsy Cell Therapy))
Study of Arlocabtagene Autoleucel (BMS-986393) a GPRC5D-directed CAR T Cell Therapy in Adult Participants With Relapsed or Refractory Multiple Myeloma
Phase 2 Study to Evaluate Safety and Efficacy of Cretostimogene Grenadenorepvec in High-Risk NMIBC
International Collaborative Gaucher Group (ICGG) Gaucher Disease Registry & Pregnancy Sub-registry
A Study of CREXONT (Carbidopa and Levodopa) Extended-Release Capsules in Participants With Parkinson's Disease
DAREON ® -Lung-1: A Study in People With Advanced Small Cell Lung Cancer to Compare Obrixtamig Plus Atezolizumab, Carboplatin, and Etoposide Treatment With Standard Chemoimmunotherapy
Safety and Efficacy of APC-0101 in Preterm Infants With Respiratory Distress Syndrome
A Study Evaluating the Effectiveness and Safety of Risdiplam Administered in Pediatric Patients With Spinal Muscular Atrophy Who Experienced a Plateau or Decline in Function After Gene Therapy
A Study Evaluating the Effectiveness and Safety of Risdiplam Administered as an Early Intervention in Pediatric Participants With Spinal Muscular Atrophy After Gene Therapy
A Study of Toripalimab in Combination With Cisplatin and Gemcitabine in Participants With Recurrent Metastatic Nasopharyngeal Cancer
A Study of Talquetamab in Participants With Relapsed or Refractory Multiple Myeloma
A Study to Evaluate the Safety and Efficacy of a Single Dose of RABI-767 in Participants With Acute Pancreatitis
ARC-IM System to Manage Symptomatic Blood Pressure Instability Secondary to Chronic Spinal Cord Injury
Safety and Tolerability Study of ST-503 for Refractory Pain Due to Peripheral Neuropathy (Small Fiber Predominant, SFN)
Safety, Tolerability and Efficacy Study of ARCT-032 in People With Cystic Fibrosis
A Phase 1/2 Study of NRTX-1001 Neuronal Cell Therapy in Drug-Resistant Bilateral Mesial Temporal Lobe Epilepsy (MTLE)
Study With Phage for CF Subjects With Pseudomonas Lung Infection
InSpace Accelerated Rehabilitation Study
Efficacy and Safety of Novosis Putty in Transforaminal Lumbar Interbody Fusion for Patients With Lumbar Degenerative Disc Disease
PRGN-2009 in Combination With Pembrolizumab in Patients With Recurrent or Metastatic Cervical Cancer
Study to Assess the Safety, Tolerability, and Preliminary Efficacy of ST266 in Infants With Necrotizing Enterocolitis (NEC)
The HVIP+ Community Model
Testing the Addition of an Antiangiogenic Drug (Bevacizumab) to Chemotherapy (Carboplatin and Paclitaxel) Combined With Immunotherapy (Pembrolizumab) for pMMR, TP53 Mutated Endometrial Cancer
Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25
Colon Adjuvant Chemotherapy Based on Evaluation of Residual Disease
Pembrolizumab vs. Observation in People With Triple-negative Breast Cancer Who Had a Pathologic Complete Response After Chemotherapy Plus Pembrolizumab
Testing Olaparib for One or Two Years, With or Without Bevacizumab, to Treat Ovarian Cancer
Adding an Immunotherapy Drug, MEDI4736 (Durvalumab), to the Usual Chemotherapy Treatment (Paclitaxel, Cyclophosphamide, and Doxorubicin) for Stage II-III Breast Cancer
Induction Pembrolizumab and Chemotherapy Followed by Pembrolizumab Before Chemoradiation and Pembrolizumab Maintenance Compared to Standard Chemoradiation With Pembrolizumab Followed by Pembrolizumab Maintenance in High-Risk Cervical Cancer
Active Surveillance, Bleomycin, Etoposide, Carboplatin or Cisplatin in Treating Pediatric and Adult Patients With Germ Cell Tumors
Common conditions studied in Little Rock
- Schizophrenia (16 active studies)
- Acute Myeloid Leukemia (11 active studies)
- Duchenne Muscular Dystrophy (10 active studies)
- Malignant Solid Neoplasm (8 active studies)
- Obesity (8 active studies)
- Bipolar I Disorder (7 active studies)
Leading research sponsors in Little Rock
- University of Arkansas
- National Cancer Institute (NCI)
- Arkansas Children's Hospital Research Institute
- Children's Oncology Group
- SWOG Cancer Research Network
Frequently asked questions
How many paid clinical trials are currently recruiting in Little Rock?
There are approximately 502 recruiting clinical trials in Little Rock, Arkansas listed on ClinicalTrials.gov. The number changes weekly as new studies open and others close enrollment.
Do clinical trials in Little Rock pay participants?
Most recruiting trials in Little Rock compensate participants for their time, travel, and study visits. Compensation varies by sponsor, study phase, and visit requirements — the exact amount is disclosed by the study team during the informed consent process.
Who can participate in a clinical trial in Little Rock?
Eligibility depends on the specific study. Each trial defines its own inclusion criteria (age, diagnosis, medical history, prior treatments) and exclusion criteria. Both patients with specific conditions and healthy volunteers can qualify, depending on the study design.
What conditions are most commonly studied in Little Rock?
The most common conditions under active study in Little Rock include Schizophrenia (16), Acute Myeloid Leukemia (11), Duchenne Muscular Dystrophy (10), Malignant Solid Neoplasm (8), among many others. Browse the list above to explore every recruiting trial.
Are there clinical trials for healthy volunteers in Little Rock?
Yes. Healthy-volunteer studies — often early-phase pharmacology or vaccine trials — recruit in Little Rock on an ongoing basis. Use the "Healthy volunteers only" filter above to view trials that accept participants without the study's target condition.
How do I enroll in a clinical trial in Little Rock?
Click any study title above to see the full study record, including eligibility criteria, visit schedule, and the study team's contact information. Reach out to the central contact or recruiting site directly — they will guide you through screening and informed consent.
Where can I take part in paid clinical trials in Little Rock?
Recruiting research sites in Little Rock include University of Arkansas for Medical Sciences, Arkansas Children's Hospital, CARTI Cancer Center, among others. Each site lists its open studies and contact information on the study record above — call or email the site coordinator to ask about screening for a specific protocol.
What kinds of studies are recruiting in Little Rock right now?
The largest active categories in Little Rock are Cancer & tumors (133), Mental health & behavior (38), Cardiovascular (30). Use the filters above to narrow by therapeutic area, phase, age, or healthy-volunteer eligibility.
What is the address of University of Arkansas for Medical Sciences?
University of Arkansas for Medical Sciences is located at 4301 W MARKHAM ST, LITTLE ROCK, AR 72205-7101. Use the Google Maps link in the intro above to get directions.
How do I contact University of Arkansas for Medical Sciences?
You can reach University of Arkansas for Medical Sciences by phone at (501) 614-2830. For questions about a specific trial, use the study coordinator contact listed on the individual study record — click any trial title above to open it.